Day 2 :
Keynote Forum
Myron R Szewczuk
Queen’s University, Canada
Keynote: Cancer promotes an angiogenic and proinflammatory cytokine response in the host microenvironment for the development of tumorigenesis
Biography:
For the past 37 years, Dr Szewczuk is Full Professor of Immunology and Medicine at Queen’s University, Kingston, ON Canada. Prior to Queen’s, he was Professor of Mucosal Immunology and Pathology at McMaster University, Hamilton, ON, Canada. He did his Postdoctoral training in cellular immunology at Cornell University Medical College, New York city, USA. Dr Szewczuk’s recent research has focused on the role of glycosylation in receptor activation with a particular focus of TOLL-like, nerve growth factor Trk, EGFR and insulin receptors. He has discovered a novel receptor-signaling platform and its targeted translation in multistage tumorigenesis
Abstract:
Stromal cells and growth factors play important roles during tumor initiation and progression. Growth factors not only mediate normal biological processes such as development and tissue repair but also tumorigenesis by contributing to proliferation and transformation in neoplastic cells. This study investigated the host angiogenic and pro-inflammatory cytokines during tumor initiation and progression in heterotopic xenografts of eGFP-MIAPaCa-2 tumors growing in RAGxCγ double mutant mice. The time-to-tumor progression revealed significant host cytokine responses initiated by the cancer cells in order for them to establish neo-vasculature for tumor growth. Here, cancer cells maneuver multiple hosts circulating angiogenic and pro-inflammatory cytokines by significantly reducing host angiostatic and pro-inflammatory cytokines that restrain tumor development and increasing those that are needed. Oseltamivir phosphate (OP) monotherapy when tumor volume reached 100-200mm3 revealed a reversal in some of the anti-angiogenic and pro-inflammatory cytokines in preventing tumor growth. The data signify several important cytokines as potential biomarkers for therapy. The findings identify for the first time how cancer cells surreptitiously use multiple host cytokines for tumor initiation and progression, all of which can be targeted by OP monotherapy
Keynote Forum
Rola Shaheen
Peterborough Regional Health Center, Canada
Keynote: The road map for high quality breast imaging practice
Biography:
Rola Shaheen, Medical Director and Chief of Radiology at Peterborough Regional Health Center in Ontario- Canada. She serves as provincial lead for Mammography Quality Management Program in partnership with Cancer Care Ontario and College of Physicians and Surgeons of Ontario and Regional Breast Imaging Lead for Mississauga- Halton Central West Region in OBSP. Previously she worked at SEHA in Abu Dhabi as lead breast imaging radiologist and chief of women’s imaging at Mafraq hospital. Graduated from Faculty of Medicine of Jordan University and completed radiology residency at University of Toronto. Completed women’s imaging fellowship at BIDMC-teaching hospital of Harvard Medical School.
Abstract:
Breast imaging practice is one of the most complex yet inetersting practices in any radiology department. Complexity stems from the fact that breast imaging is highly regulated specialty with key indicators meaurements in addition to the essential need for utilization of multi-modality equipments and image guided interventions to accurately establist the diagnosis of breast cancer and plan management accordingly. Providing high quality performance in breast imaging regradless of the setting is crucial to avoid any delay in diagnosis of breast cancer and equally important to is avoid unnecessary furher imaging or interventions to minimize patients’ anxiety and to enusre cost effectiveness. The knots and bolts for successful breast imaging practice include clear understanding of the highly regulated specialty in light of the collaborative multidisciplinary commitment. This talk will focus on providing an understanding of the multifaceted breast imaging practice of screening, diagnostic and interventions, and how the multimodality equipments (digital mammography, tomosynthesis, ultrasound & MRI) can serve realistically in each setting, in an effort to provide a high quality pateint centric, and cost effective practice. Pearls and pifalls will also be presented to help radiologists in every day breast practice.
Keynote Forum
Abdelmohsen Hussien
SUNY Upstate Medical University, USA
Keynote: Early Breast Cancer: Improve your ability to find it
Biography:
Hussien is an American board certified radiologist. He has graduated from Cairo University Medical School. He also had his radiology residency in Egypt. He finished a four years of radiology fellowships in the University of Rochester in Neuroradiology, Body imaging and women’s imaging. He practiced women’s imaging for about 5 years, four of them at the University of Rochester. During which he was able to successfully make a great change in breast cancer detection rate in one of the affiliated locations in the town of Canandaigua. He then moved to SUNY Upstate Medical University for a wider scope of neuroradiology practice and research.
Abstract:
- Cancer Therapy | Cancer Imaging | Nuclear Medicine | Radiology Imaging | Proton Theray Nuclear Medicine | Paediatric Oncology | Computer Assisted Tomography | Ultrasound Imaging | Musculoskeletal
Session Introduction
Mosa Alhamami
University of Toronto, Canada
Title: Manganese-enhanced magnetic resonance imaging of breast cancer cells
Biography:
Abstract:
There has been continued interest in engineering MRI contrast agents (CAs) and evaluating their diagnostic efficacy to overcome issues associated with clinically-approved CAs such as Gd-DTPA. Of particular interest are intracellular CAs that can provide sensitive identification of labelled cells, opening the possibility of directly detecting early changes driving cancers at the cellular level before vasculature has been fully formed. To further explore the capabilities of intracellular CAs in T1-weighted MRI of breast cancer, this work aimed at (1) demonstrating the potential of MnCl2-enhanced MRI to detect and characterize early small breast tumors in vivo (2) investigating the potential of manganese-porphyrin-enhanced MRI for sensitive detection of multiple clinical subtypes of breast cancer cells (3) utilizing quantitative MRI to demonstrate the role the balance between hydrophilicity and hydrophobicity plays in developing CAs for effective T1-weighted MRI of cancer. This work has shown that MnCl2, unlike Gd-DTPA, provided enhancement of the entire tumor mass, depicting both tumor borders and interior morphology. At the early stage of tumor growth, MnCl2 also enabled cancer subtype-dependent differential enhancement and characterization. Moreover, this work demonstrated the superior T1 enhancement capabilities of manganese porphyrins over Gd-DTPA of multiple clinical subtypes of breast cancer cells at 3.0T. Also, using quantitative MRI, the more hydrophobic manganese porphyrin, MnTPPS3NH2, is shown to be a more sensitive T1 CA than MnTPPS4 for cellular imaging of breast cancers. Such sensitive cellular detection can potentially lead to lowering the dose needed to achieve positive enhancement and merits further future in vivo investigation
Carlos Zepeda-Velázquez
Ontario Institute for Cancer Research,Canada
Title: The discovery and evaluation of OICR-9429: A small molecule antagonist of the Wdr5-Mll interaction
Biography:
Abstract:
At a fundamental level, gene expression is regulated by epigenetic histone modifications. Histone methyltransferases catalyze the transfer of the methyl group from S adenosylmethionine to specific lysine residues on histones. Mixed lineage leukemia 1 (MLL1) is a methyltransferase that methylates lysine 4 on histone H3 (H3K4me3) and is an important regulator of the haemopoietic system. Dysregulation of MLL1 is often associated with acute myeloid and lymphoid leukemias, making it an attractive therapeutic target. WD40 repeat protein 5 (WDR5) is a component of the multiprotein MLL1 complex that is essential for its methyltransferase activity, and disruption of the WDR5/MLL1 interaction may therefore present a viable therapeutic option for the treatment of MLL-dependent leukemias. Employing structure-based design principles and cheminformatic tools, compounds that bind to WDR5 with low nanomolar affinities were synthesized. Of the various small molecules assessed, OICR-9429 demonstrated the most potent activity with KD values of 51 nM (Biacore), 64 nM (FP) and 52 nM (ITC). OICR9429 also disrupts the interaction of WDR5 with MLL1 and RbBP5 in cells with IC50 values below 1 µM
Romina Geraldine D’Souza
Christian Medical College Hospital, India
Title: Can we tell? MRI parameters to predict occult lymph node metastasis in oral cavity malignancies
Biography:
Dr Romina Geraldine D’Souza, she had completed my MD Radiology from Father Muller Medical college Mangalore, India, Diplomate of the National Board in Radiology and currently doing a fellowship in Crossectional radiology in Christian Medical College, Vellore India and FRCR 2
Abstract:
Mohammed Naeem
King Abdullah Specialized Children’s Hospital, Saudi Arabia
Title: Approach to wide aspects of end of life care in children
Biography:
Mohammed Naeem MD, FAAP, FCCP has vast interests and experience in care and development of children and adolescents. His passion gears towards constructing and implementing scientific models to improve systems targeting primary, secondary and tertiary care. His ideology takes a positive direction through his in-depth analyses and vision and further to explore multiple ways that would help understand the complex pathological phenomenon and planning to design and implement strategies to overcome these. His particular interest and expertise involves population of children and adolescents requiring intensive care. He had been utilizing his vast experience of research, clinical care, patient safety and strategic planning to ambitiously achieve his goals. Through multiple levels of participation in care and strategic planning relevant to diverse patient population, he had been very successful to make his contributions and judgments being heard and taken in considerations
Abstract:
Yoshiaki Omura
New York Medical College, USA